In BioCentury’s Venture Report: Oncomatryx, Quibin raise cash in Spain; Atalanta draws $97M; Forbion’s BioEconomy Fund

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more

Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more

Plus: Progentos’ launch; series B rounds for AltruBio, Pheon and Grey Wolf; a series A for Vienna-based Ygion; and more

Highlights include accelerated approval of first MASH therapy; plus Merck’s disease-modifying PAH therapy and Idorsia’s antihypertensive 

Approval marks the start of a new disease-modifying treatment paradigm for the rare disease and related indications

BioCentury’s roundup of translational innovations

Plus: J&J’s Rybrevant raises the bar and updates from Harbinger, Gritstone, Merck, Immunovant, Evozyne, PTC  

Sotatercept meets primary and most secondary endpoints in Phase III pulmonary arterial hypertension study